Navigation Links
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Date:8/29/2010

in New York (NYSE: SNY).

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth o
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
2. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
3. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
4. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
5. Study Shows Machine Perfusion Significantly Improves Transplant Results
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
8. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
9. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
10. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
11. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... for odour control projects in North America , ... . "Bidding activity in 2015 continues to be ... a high volume year for bidding in 2014, we are pleased ... recent orders reflect the organization,s renewed focus on select market segments ...
(Date:3/3/2015)... DIEGO , March 3, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and Chief Executive Officer ... Global Healthcare Conference in Miami.   The ... 10:15am ET (7:15am PT).  The presentation will be webcast ... http://www.neurocrine.com .   Listeners are encouraged ...
(Date:3/3/2015)... 2015 Adaptive Biotechnologies announced today that ... Board of Director as Chair of the Audit Committee. ... Chad oversees all finance, treasury and accounting functions. Since ... finance, treasury and accounting functions, and led the finance ... 2013, he was named Puget Sound Business Journal,s CFO ...
(Date:3/3/2015)... 03, 2015 Crown Bioscience, Inc., a ... launched a new Life Science division specializing in in ... , The first products released include in vivo ... soon to be released in vivo grade monoclonal antibodies ... expand their life science portfolio with additional antibody products ...
Breaking Biology Technology:Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2Crown Bioscience Launches Life Science Product Catalog 2
... Part of Genetic Testing Process Says ... American College of Medical Genetics, BETHESDA, ... before, ranging from home DNA test kits, tests that can,help ... tests. Along with greater availability of genetic tests and,increased Direct-to-Consumer ...
... Yves Lionel Assant is,the new Chairman of Gerresheimer,s ... was already a member of the Supervisory Board. ... position for personal reasons. He,remains a member of ... & life science supply and services,company with market ...
... international team including scientists from the London Centre for ... of the National Academy of Sciences (PNAS) demonstrating the ... The importance of the work lies in establishing how ... produced at particle accelerators and nuclear reactors can ...
Cached Biology Technology:Statement on Direct-To-Consumer Genetic Testing 2Statement on Direct-To-Consumer Genetic Testing 3Imaging quantum entanglement 2
(Date:2/24/2015)... Feb. 24, 2015 This report analyzes the worldwide markets ... Segments: Face Biometrics, and Voice Biometrics. The report provides separate comprehensive ... Japan , Europe , Asia-Pacific ... Africa , and Latin America . Annual ... Also, a seven-year historic analysis is provided for these markets. Market ...
(Date:2/23/2015)... OXFORD, Conn. , Feb. 23, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... it has filed provisional patent 62114357 for ... With this patent, NXT-ID introduces a new groundbreaking payment ... and the payment account may only be accessed if ...
(Date:2/18/2015)... Feb. 18, 2015  Cepheid (NASDAQ: CPHD ) ... following conferences, and invited investors to participate via webcast. ... MA Tuesday, March 3, 2015 at 11.20 a.m. ... Orlando, FL Wednesday, March 4, 2015 at ... access the live webcasts for these events, please visit Cepheid,s ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2
... TorontoResearchers at the University of Toronto, The Hospital ... University of British Columbia have identified a new treatment ... and an estimated 10% of common colds. The virus, ... most common reason for hospitalization of infants and children ...
... led by St. Jude Children,s Research Hospital scientists has ... childhood eye tumor retinoblastoma. Their work also settles a ... as scrambled as the developmental pathways at work in ... particular type of cell, researchers showed that retinoblastoma is ...
... A recent study suggests that parasites in fish, including ... impacts on fish health than has been assumed, and could ... land use changes cause salmon mortality. It,s not just ... research found, but their numbers that can build up over ...
Cached Biology News:Researchers map pathway of infection for a common, potentially life-threatening respiratory virus 2Childhood eye tumor made up of hybrid cells with jumbled development 2Childhood eye tumor made up of hybrid cells with jumbled development 3Parasite loads an underlying cause of salmon mortality, linked to land use changes 2
This bispecific antibody complex has been tested for efficient depletion of CD41+ cells using the StemSep ; negative immunomagnetic cell separation system....
... Eclipse C1 Plus is a modular confocal ... imaging with an ultra-compact and lightweight design. ... C1 Plusboost optical performance to 400nm andits ... alsoincludes support for X and Y scan ...
... integrated digital microscope and camera system that ... optical adjustment or software installation. Built on ... combines simplicity and advanced technology for users ... viewing of a macro image and a ...
... The TUNEL-based assay kit provides ... control cells for convenient detection of ... tissue sections. The incorporation of BrdU ... than biotinylated or digoxigenylated methods. Results ...
Biology Products: